You just read:

SCYNEXIS Announces Special Protocol Assessment (SPA) Agreement with FDA for Phase 3 Study Evaluating Oral Ibrexafungerp for the Prevention of Recurrent Vulvovaginal Candidiasis (VVC) (CANDLE Study)

News provided by

SCYNEXIS, Inc.

Jul 24, 2019, 08:00 ET